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Abstract
Over the past decade, several targeted therapies (e.g. imatinib, dasatinib, nilotinib) have
been developed to treat Chronic Myeloid Leukemia (CML). Despite an initial response to
therapy, drug resistance remains a problem for some CML patients. Recent studies have
shown that resistance mutations that preexist treatment can be detected in a substan-
tial number of patients, and that this may be associated with eventual treatment failure.
One proposed method to extend treatment efficacy is to use a combination of multiple
targeted therapies. However, the design of such combination therapies (timing, sequence,
etc.) remains an open challenge. In this work we mathematically model the dynamics of
CML response to combination therapy and analyze the impact of combination treatment
schedules on treatment efficacy in patients with preexisting resistance. We then propose an
optimization problem to find the best schedule of multiple therapies based on the evolution
of CML according to our ordinary differential equation model. This resulting optimiza-
tion problem is nontrivial due to the presence of ordinary different equation constraints
and integer variables. Our model also incorporates realistic drug toxicity constraints by
tracking the dynamics of patient neutrophil counts in response to therapy. Using realis-
tic parameter estimates, we determine optimal combination strategies that maximize time
until treatment failure.
Author Summary
Targeted therapy using imatinib, nilotinib or dasatinib has become standard treatment
for chronicle myeloid leukemia. A minority of patients, however, fail to respond to treat-
ment or relapse due to drug resistance. One primary driving factor of drug resistance are
point mutations within the driving oncogene. Laboratory studies have shown that differ-
ent leukemic mutants respond differently to different drugs, so a promising way to improve
treatment efficacy is to combine multiple targeted therapies. We build a mathematical
model to predict the dynamics of different leukemic mutants with imatinib, nilotinib and
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dasatinib, and employ optimization techniques to find the best treatment schedule of com-
bining the three drugs sequentially. Our study shows that the optimally designed combina-
tion therapy is more effective at controlling the leukemic cell burden than any monotherapy
under a wide range of scenarios. The structure of the optimal schedule depends heavily
on the mutant types present, growth kinetics of leukemic cells and drug toxicity param-
eters. Our methodology is an important step towards the design of personalized optimal
therapeutic schedules for chronicle myeloid leukemia.
Introduction
Chronic Myeloid Leukemia (CML) is an acquired hematopoietic stem cell disorder lead-
ing to the over-proliferation of myeloid cells and an increase in cellular output from the
bone marrow that is often associated with splenomegaly. The most common driving mu-
tation in CML is a translocation between chromosomes 9 and 22 that produces a fusion
gene known as BCR-ABL. The BCR-ABL protein promotes proliferation and inhibits cell
apoptosis of myeloid progenitor cells and thereby drives expansion of this cell population.
By targeting the BCR-ABL oncoprotein, imatinib (brand name Gleevec) is able to induce a
complete cytogenetic remission in the majority of chronic phase CML patients. A minority
of patients, however, either fail to respond or eventually develop resistance to treatment
with imatinib [1]. It is thought that a primary driver of this resistance to imatinib is point
mutations within the BCR-ABL gene. A recent study utilizing sensitive detection meth-
ods demonstrated that a small subset of these mutations may exist before the initiation of
therapy in a significant fraction of patients, and that this status is correlated with eventual
treatment failure [2]. Second generation agents such as dasatinib and nilotinib have been
developed and each has shown efficacy against various common mutant forms of BCR-ABL.
This leads to the observation that the various mutant forms of BCR-ABL result in CML
that have unique dynamics under therapy, and that combinations of these inhibitors may
be necessary to effectively control a rapidly evolving CML population. Patients with CML
often die due to transformation of the disease into an acute form of leukemia known as
blast crisis. It has been shown that blast crisis is due to the accumulation of additional
mutations in CML progenitor cells [3].
The goal of this work is to leverage the differential responses of CML mutant strains
to design novel sequential combination treatment schedules using dasatinib, imatinib and
nilotinib that optimally control leukemic burden and delay treatment failure due to pre-
existing resistance. We develop and parametrize a mathematical model for the evolution
of both wild-type (WT) CML and mutated (resistant) CML cells in the presence of each
therapy. Then we formulate the problem as a discrete optimization problem in which a
sequence of monthly treatment decisions is optimized to identify the temporal sequence
of imatinib, dasatinib, and nilotinib administration that minimizes the total CML cell
population over a long time horizon.
There has been a significant amount of work done in the past to mathematically model
CML. For example, in [4] the authors developed a system of ordinary differential equations
(ODEs) that model both the normal progression from stem cell to mature blood cells
and abnormal progression of CML. A hierarchical system of differential equations was
used to model the response of CML cells to imatinib therapy in [5]; this model fit the
biphasic nature of decline in BCR-ABL positive cells during imatinib treatment. In [6] the
authors investigated the number of different resistant strains present in a newly diagnosed
chronic phase CML patient. An optimal control approach was utilized to optimize imatinib
scheduling in [7]. Particularly relevant to our work is [8, 9] where the authors investigated
simultaneous continuous administration of dasatinib, nilotinib and imatinib; in particular,
they explored the minimal number of drugs necessary to prevent drug resistance. In the
current work, we focus on understanding the optimal administration schedule of multiple
therapies to prevent resistance, and studying the impact of toxicity constraints on optimal
scheduling. Since several of the available tyrosine kinase inhibitors (TKI) share similar
toxicities (in particular neutropenia, see e.g., [10, 11, 12]) combining them together can
lead to elevated risk of adverse events. Thus we consider sequential combination therapies
in which only one TKI may be administered at a time. Moreover, it has been shown
that the risk of treatment failure and blast crisis are highest within the first 2 years from
diagnosis [1]. Therefore it is possible that optimized, sequential single agent therapy may
be sufficient to minimize the risk of treatment failure. Allowing only one treatment at a
time leads to a complex, time-dependent discrete optimization problem.
Another line of research closely related to the current work is the use of optimal control
techniques in the design of optimal temporally continuous drug concentration profiles (see,
e.g., review articles [13, 14] and the textbook [15]). In this field the tools of optimal
control such as the Pontryagin principle and the Euler-Lagrange equations are used to find
drug concentration profiles that result in minimal tumor cell populations under toxicity
constraints. Particularly relevant to the current work is [16] where the authors searched
for optimal anti-HIV treatment strategies. They dealt with the similar problem of treating
heterogeneous populations with multiple drugs. One major drawback of these works is
the fact that it is nearly impossible to to achieve a specific optimal continuous drug-
concentration profile in patients, since drug concentration over time is a combined result of
a treatment schedule (e.g. sequence of discrete oral administrations) and pharmacokinetic
processes in the body including metabolism, elimination, etc. Thus the clinical utility of
an optimal continuous drug concentration profile is limited. In contrast to these previous
works, here we model the optimization problem as a more clinically realistic sequence
of monthly treatment decisions. Imposition of this fixed discrete set of decision times
leads to a challenging optimization problem. Such dynamical systems are referred to as
‘switched nonlinear systems’ in the control community [17], and our problem additionally
imposes fixed switching times. In this work we will leverage the system structure and tools
from mixed-integer linear optimization [18] to solve this problem numerically, resulting in
optimal therapy schedules that are easy to implement in practice.
Computational framework
Model of CML dynamics. We consider an ODE model of the differentiation hierarchy
of hematopoietic cells, adapted from [5, 19, 20]. Stem cells (SC) on top of the hierarchy
give rise to progenitor cells (PC), which produce differentiated cells (DC), which in turn
produce terminally differentiated cells (TC). This differentiation hierarchy applies to both
normal and leukemic cells [21]. We consider in our model leukemic WT cells as well as
pre-existing BCR-ABL mutant cell types. We use type 1, type 2, and type i (3 ≤ i ≤ n)
cells to denote normal, leukemic WT, and (n−2) leukemic mutant cells; layer 1, 2, 3, 4 cells
to denote SC, PC, DC, and TC; and drug 0, 1, 2, 3 to denote a drug holiday, nilotinib,
dasatinib, and imatinib, respectively. Let xl,i(t) denote the abundance of type i cell at
layer l and time t, and x(t) = (xl,i(t)) be the vector of all cell abundance at time t. If
drug j ∈ {0, 1, 2, 3}) is taken from month m to month m + 1, then the cell dynamics are
modeled by the following set of ODEs.
x˙(t) = f j(x(t)), t ∈ [m∆t, (m+ 1)∆t],(1a)
x(m∆t) = xm,(1b)
for some function f j , where ∆t = 30 days and xm is the cell abundance at the beginning
of month m. The concrete form of function f j under drug j is described as follows.
SC level x˙1,i = (b
j
1,iφi − dj1,i)x1,i, i = 1, . . . , n(2a)
PC level x˙2,i = b
j
2,ix1,i − dj2,ix2,i, i = 1, . . . , n(2b)
DC level x˙3,i = b
j
3,ix2,i − dj3,ix3,i, i = 1, . . . , n(2c)
TC level x˙4,i = b
j
4,ix3,i − dj4,ix4,i, i = 1, . . . , n.(2d)
Here we describe the function of each parameter of this model. For a detailed discussion
of how these parameters were estimated from biological data, please see section A of the
Appendix. Type i stem cells divide at rate bj1,i per day under drug j. The production rates
of type i progenitors, differentiated cells, and terminally differentiated cells under drug j
are bjl,i per day for l = 2, 3, 4, respectively. The type i cell at layer l dies at rate d
j
l,i per day
under drug j, for each i, l and j. The competition among normal and leukemic stem cells is
modeled by the density dependence functions φi(t), where φi(t) = 1/(1+pi
∑n
i=1 x1,i(t)) for
each i; these functions ensure that the normal and leukemic stem cell abundances remain
the same once the system reaches a steady state. The parameter p1 (resp. p2) is computed
from the equilibrium abundance of normal (resp. leukemic WT) stem cells assuming only
normal (resp. leukemic WT) cells are present, and we set pi = p2 for each i ≥ 3. In
particular, p1 = (b
0
1,1/d
0
1,1 − 1)/K1 and p2 = (b01,2/d01,2 − 1)/K2, with K1 (resp. K2) being
the equilibrium abundance of normal (resp. leukemic WT) stem cells assuming only normal
(resp. leukemic WT) cells are present.
Toxicity modeling. One of the most common side effects of TKIs in CML is neutropenia,
or the condition of abnormally low neutrophils in the blood. Neutropenia is defined in terms
of the absolute neutrophil count (ANC). To incorporate toxicity constraints we develop a
model of the dynamics of the patient’s ANC in response to each therapy schedule. We
then constrain our optimization problem by considering only schedules during which the
patient’s ANC stays above an acceptable threshold level Lanc. Typically, ANC at diagnosis
is within normal limits (between 1500−8000/mm3); thus we set each patient’s initial ANC
to be 3000/mm3. Treatment with imatinib, dasatinib and nilotinib all result in reduction of
the ANC at varying rates. Neutropenia is defined as an ANC level below Lanc = 1000/mm
3.
If a patient’s ANC falls below the threshold, a drug holiday is required at the next monthly
treatment decision stage. During a drug holiday, ANC level will recover back to safe levels.
To model this process, we assume the patient’s ANC decreases at rate danc,j per month
taking drug j, for j = 1, 2, 3. During a drug holiday, ANC increases at rate banc per month
but never exceeds the normal level of Uanc = 3000/mm
3. More specifically, let ym denote
the ANC level at the beginning of month m and the binary variable zm,j indicate whether
drug j is taken in month m or not, i.e., zm,j = 1 (resp. zm,j = 0) indicates drug j is (resp.
not) taken in month m. The kinetics of ANC is modeled through the truncated linear
function
ym+1 = r(ym, zm,0, zm,1, zm,2, zm,3) = min{ym + banczm,0 −
∑
j∈{1,2,3}
danc,jz
m,j , Uanc}.
For example, after a patient with ANC level ym takes a drug holiday in month m, her ANC
level at the beginning of month m+1 becomes ym+ banc if y
m+ banc is not higher than the
normal level Uanc, or Uanc if y
m + banc exceeds Uanc. If the patient instead takes nilotinib
in month m, then her ANC level at the beginning of month m + 1 becomes ym − danc,1.
The parameters governing ANC rate of change are provided in section A of the Appendix.
Treatment optimization problem
Assume the initial population of each cell type is known. Our goal is to select a treatment
plan to minimize the tumor size at the end of the planning horizon subject to certain toxicity
constraints. We call this the Optimal Treatment Plan problem (OTP). Each treatment
plan is completely characterized by a temporal sequence of monthly treatment decisions
over a long time horizon. Between each monthly treatment decision, the dosing regimen
is identical from day to day. The standard regimens for each drug, which we will utilize
throughout the work, are 300mg twice daily for nilotinib, 100mg once daily for dasatinib,
and 400mg once daily for imatinib [22]. For example, let 1 denote nilotinib, 2 - dasatinib,
3 - imatinib, and 0 - drug holiday. Then the sequence {1, 1, . . . , 1} represents that the
patient takes the standard nilotinib regimen, 300mg twice daily, every day, every month.
The sequence {2, 0, 2, 0, . . .} represents that the patient alternates between the standard
dasatinib regimen, 100mg once daily, and a drug holiday on alternate months.
We introduce the binary decision variables zm,j to indicate whether drug j is taken in
month m or not, for each j = 0, 1, 2, 3 and m = 0, 1, . . . ,M − 1. An assignment of values
to all zm,j variables that satisfy all constraints in the optimization model gives a feasible
treatment plan.
The optimization problem. Note the total leukemic cell abundance at day t is given by∑
l≥1
∑
i≥2 xl,i(t). The OTP can be formulated as the following mixed-integer optimization
problem with ODE constraints.
min
∑
l≥1
∑
i≥2
xl,2(M∆t)
(3a)
s.t. x˙(t) =
3∑
j=0
zm,jf
j(x(t)), t ∈ [m∆t, (m+ 1)∆t],m = 0, 1, . . . ,M − 1,
(3b)
3∑
j=0
zm,j = 1, m = 0, 1, . . . ,M − 1,(3c)
ym+1 = r(ym, zm,0, zm,1, zm,2, zm,3), m = 0, 1, . . . ,M − 1,(3d)
ym ≥ Lanc, m = 0, 1, . . . ,M,(3e)
zm,j ∈ {0, 1}, j = 0, 1, 2, 3,m = 0, 1, . . . ,M − 1(3f)
x(0) = x0, y0 is given.(3g)
To summarize the previous display, in equation (3a) we state that our objective is to
minimize the leukemic cell population at the end of the treatment horizon. In equation (3b)
we stipulate that the cell dynamics are governed by the system of differential equations
given by (2). Together (3c) and (3f) stipulate that during each time period we administer
either one drug or no drug. Equations (3d) and (3e) reflect the toxicity constraints described
above.
The OTP problem is a mixed-integer nonlinear optimization problem, in which some
constraints are specified by the solution to a nonlinear system of ODEs (3b). This opti-
mization problem is beyond the ability of state-of-the-art optimization software. However,
if we assume the TKI therapies do not affect the stem cell compartment, then it is possible
to handle the ODE constraints numerically. This is because the non-linearities in the ODE
model are only present in the stem cell compartment, and the remaining compartments
are modeled by linear differential equations. Thus we are able to build a refined linear
approximation to the ODE constraints (see Section C of the Appendix), and recast the
problem as a mixed-integer linear optimization problem (see Section B of the Appendix).
A quick reference for notation. Below we summarize our notation for the ease of the
reader.
• I = {1, 2, . . . , n}: the set of cell types. Type 1 denotes normal cells, type 2 denotes
leukemic WT cells, and type i (3 ≤ i ≤ n) denotes one type of leukemic mutants.
• L = {1, 2, . . . , L}: the set of cell layers. We have L = 4, and layer 1, 2, 3 and 4
denotes SC, PC, DC, and TC, respectively.
• J = {0, 1, 2, . . . , J}: The set of drugs for CML. We have J = 3, drug 0 refers to
a drug holiday, and drug 1 to drug 3 refers to nilotinib, dasatinib, and imatinib,
respectively.
• M = {0, 1, . . . ,M}: the set of months for treatment.
• ∆t: the duration during which a patient takes one drug before deciding to switch
to another drug or take a drug holiday. We set ∆t = 30 days.
• K1: the equilibrium abundance of normal stem cells when only normal cells are
present.
• K2: the equilibrium abundance of leukemic WT stem cells when only leukemic cells
are present.
• bjl,i: the production rate of type i cell at layer l under drug j.
• djl,i: the death rate of type i cell at layer l under drug j.
• banc: the average increase (/mm3) of the ANC in a patient without any drug after
time ∆t.
• danc,j : the average decrease (/mm3) of ANC in a patient under drug j after time
∆t.
• Lanc: The lower limit of the ANC. We assume that the patient develops neutropenia
if the ANC is less than Lanc, at which a drug holiday needs to be taken.
• Uanc: The normal level of ANC.
Results
In this work we consider the dynamics of CML response to single-agent and combination
schedules utilizing the standard therapies imatinib, dasatinib and nilotinib.
Evolution of preexisting BCR-ABL mutants under standard monotherapy. We
first utilize the model to demonstrate the dynamics of CML populations with preexisting
BCR-ABL mutations under monotherapy with the standard therapies imatinib, dasatinib
and nilotinib. Recall that the standard dosing regimens are 300mg twice daily for nilotinib,
100mg once daily for dasatinib, and 400mg once daily for imatinib [22]. Growth rate
parameters for each cell type in the model are estimated using in vitro IC50 values reported
in [23] for each drug. The initial cell populations at the start of therapy are derived by
running the model starting from clonal expansion of a single leukemic cell in a healthy
hematopoietic system at equilibrium [24] until CML detection (when the total leukemic
burden reaches approximately 1012 cells [25]). At this point the total cell burden is 2-3
times the normal cell burden in a healthy individual and thus the total leukemic cells make
up approximately 77% of the total cell population; this is consistent with clinical reports
[26]. Details on deriving the initial cell abundances at diagnosis are provided in section A
of the Appendix.
In the first example we consider a patient harboring a low level of the BCR-ABL mutant
F317L (which is resistant to dasatinib) before the initiation of TKI therapy. The initial
population conditions are given in Table 1 with the leukemic WT and F317L cells taking
up 95% and 5% of the leukemic cells, respectively.
We plot in Fig 1 the cell dynamics over 120 months for four treatment plans: (1) nilo-
tinib monotherapy (2) dasatinib monotherapy, (3) imatinib monotherapy, (4) no therapy
- control. We observe that as predicted, the disease burden responds well to imatinib and
Table 1. The initial cell abundance.
normal cell Wild-type F317L
SC 7.34× 104 2.80× 105 1.48× 104
PC 1.61× 107 3.87× 107 2.04× 106
DC 3.24× 109 1.03× 1010 5.40× 108
TC 3.24× 1011 1.03× 1012 5.40× 1010
nilotinib; the percentage of cancerous cells after a 24 month treatment drops to 0.19% with
nilotinib and 0.26% with imatinib, respectively. However, the F317L mutant population
is fairly resistant to dasatinib; we observe that the percentage of cancerous cells after 24
months is 58.1% with dasatinib and 95.4% with no treatment. Over the 120 month pe-
riod dasatinib treatment provides only modest improvement over the ‘no drug’ option in
controlling the F317L population; however, dasatinib remains quite effective in controlling
the WT leukemic population. It is interesting to note that overall, nilotinib is the most
effective in controlling both the WT and F317L leukemic populations. However, nilotinib
also negatively impacts the healthy cell population more severely than imatinib, which
is slightly less effective in controlling the leukemic populations. This suggests that some
trade-offs between these drugs exist, and these trade-offs may be exploited in designing
combination therapies.
In the next example we consider a patient with BCR-ABL mutant type M351T preex-
isting therapy. In contrast to the previous example, this commonly occurring mutant has
been found to be partially sensitive in varying degrees to all three therapies. The initial
conditions are given in Table 2. Once again we have assumed that WT and M351T cells
take up 95% and 5% of total leukemic cells, respectively.
Table 2. The initial cell abundance.
Normal cell Wild-type M351T
SC 7.34× 104 2.80× 105 1.48× 104
PC 1.61× 107 3.87× 107 2.04× 106
DC 3.24× 109 1.03× 1010 5.40× 108
TC 3.24× 1011 1.03× 1012 5.40× 1010
In Fig 2 the cell dynamics over 120 months for the four standard treatment plans are
plotted: (1) nilotinib monotherapy (2) dasatinib monotherapy, (3) imatinib monotherapy,
(4) no therapy - control. Since the M351T mutant is responsive to each drug in contrast to
the previous example, the percentage of cancerous cells after a 24 month treatment drops to
0.18% with nilotinib, 0.18% with dasatinib, and 0.25% with imatinib, respectively. Without
treatment, the percentage of cancerous cells after 24 months is 95.4%. Here, we observe
that although nilotinib is more effective than dasatinib in controlling the total mutant
M351T burden, the effect is reversed in the progenitor population. Higher levels of stem
and progenitor populations will lead to faster rebound during treatment breaks, suggesting
another trade-off to consider in the combination setting.
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Figure 1. Long term dynamics of healthy, WT leukemic and
F317L mutant leukemic cell populations under treatment with
standard regimen monotherapy nilotinib (blue), dasatinib (yel-
low), imatinib (green) and no drug (orange). The dynamics of
healthy normal cells with mono imatinib (green) and no drug (orange) co-
incide. Initial conditions are provided in Table 1 and parameter choices are
provided in Appendix A.
Optimization of combination therapies. We next solve the discrete optimization prob-
lem to identify sequential combination therapies utilizing imatinib, dasatinib and nilotinib
to optimally treat CML patients with preexisting BCR-ABL mutations. We consider sched-
ules in which a monthly treatment decision is made between one of four choices: imatinib,
dasatinib, nilotinib, and drug holiday. During months in which one of the three drugs is
administered, the dosing regimen is fixed at 300mg twice daily for nilotinib, 100mg once
daily for dasatinib, and 400mg once daily for imatinib. In the following we optimize over
feasible treatment decision sequences that result in a minimal leukemic cell burden after 3
years. Each treatment plan is completely characterized by a temporal sequence of drugs
over a long time horizon.
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Figure 2. Long term dynamics of healthy, WT leukemic and
M351T mutant leukemic cell populations under treatment with
standard regimen monotherapy nilotinib (blue), dasatinib (yel-
low), imatinib (green) and no drug (orange). The dynamics of
healthy normal cells with mono imatinib (green) and no drug (orange) coin-
cide. Initial conditions are provided in 1 and parameter choices are provided
in Appendix A.
Optimal therapy for preexisting M351T mutation, no toxicity constraints. In our first ex-
ample we assume that the mutant M351T preexists therapy. For demonstration purposes
no toxicity constraint is considered in this example. The initial cell populations are given
in Table 2. The remaining parameters are described in Section A. Note that WT and
M351T leukemic cells comprise 95% and 5% of leukemic cells, respectively. The optimal
schedule we obtain for this scenario is provided in Table 3. The proposed combination
therapy is similar to the monotherapy using dasatinib, but switches to nilotinib towards
the end of the 36 month time horizon. We note that the optimization result is robust to
changes in the initial abundance of the leukemic mutant cells; increasing the frequency of
initial M351T mutants to 50% of the leukemic population results in an almost identical
optimal schedule (data not shown).
Table 3. Optimized treatment schedule for preexisting M351T.
Optimal combination 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 1 1
Initial conditions are provided in Table 2. No toxicity constraints. Recall that 0 - Drug Holiday,
1 - Nilotinib, 2 - Dasatinib, and 3 - Imatinib.
In Fig 3 we compare the performance of 4 different schedules including the optimized
schedule. Amongst the four schedules tested the optimal schedule provides the lowest
leukemic cell burden at the 36 month mark. It is interesting to see that there is no single
best drug. For monotherapy, it is best to use nilotinib if the treatment horizon is shorter
than 12 months, and dasatinib if the treatment horizon longer than 12 months. The
proposed combination therapy performs better than three monotherapies at the 36 month
mark: the leukemic cell population at the end of 36 months is 2.75×107 with the proposed
combination therapy and 5.92 × 107 with dasatinib (the best monotherapy). We can see
that the proposed optimal treatment schedule leads to more than 50% reduction on final
leukemic cell abundances over the best monotherapy. Figure 3 also shows that imatinib
has less efficacy than nilotinib or dasatinib in reducing the leukemic cell burden when WT
and M351T are present. An important question is, why does the optimal schedule take
that specific form. In our parameter estimates (see Appendix A) we see that dasatinib is
better at killing progenitors than nilotinib, while nilotinib is better at killing differentiated
cells. Thus the optimal schedule uses dasatinib at first to bring down the progenitor cell
population, and then switches to nilotinib near the end of the treatment horizon to decrease
the population of differentiated cells.
Optimal schedules robust to varying objective function and treatment length. We also
consider an alternative objective function in which the goal is to minimize the average
leukemic cell burden over the whole treatment horizon. Consider the scenario with M351T
mutation preexisting at initiation of therapy with no toxicity constraints again. The altered
objective function results in an optimal strategy of nilotinib monotherapy. To understand
this, we note that for minimizing area under the cell population curve it is important to
decrease the initial tumor population as quickly as possible. This tends to favor taking
nilotinib the entire time since it leads to the quickest reduction in total tumor cell pop-
ulation, by reducing differentiated and therefore terminally differentiated cells. We also
ran optimization experiments to evaluate the impact of varying the length of treatment
between 35 and 38 months; these resulted in very similar optimal schedules.
Optimal therapy for preexisting F317L mutation, no toxicity constraints. Next we consider
a patient with preexisting mutant F317L instead of M351T. According to the in vitro IC50
value reported in [23], F317 is resistant to dasatinib, and moderately resistant to nilotinib
and imatinib. The initial cell abundances are given in Table 1; the mutant leukemic cells
make up of 5% of the total leukemic cells as in the baseline model except we replace
mutant M351T with F317L. The proposed combination therapy is listed in Table 4, and
for comparison the optimal therapy for the previous example where M351T preexisted
Time (months)
0 5 10 15 20 25 30 35
To
ta
l c
an
ce
ro
us
 c
el
l a
bu
nd
an
ce
10 7
10 8
10 9
10 10
10 11
10 12
10 13
nilotinib
dasatinib
imatinib
combination
Figure 3. Plot of cell number versus time for three monotherapies
and optimal combination therapy for preexisting M351T, with no
toxicity constraints.
therapy is also provided. Note that dasatinib is used in the first 9 months and nilotinib is
used in the next 27 months in the presence of F317L.
Table 4. Optimal combination schedules.
M351T preexisting 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 1
F317L preexisting 2 2 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
In Fig 4 we show the comparison between proposed schedule and three different monother-
apies. The final leukemic cell abundances are 7.46× 107 and 9.48× 107 under the propose
schedule and monotherapy with nilotinib, respectively. The combination therapy performs
better in reducing final leukemic cell population than three monotherapies, but the im-
provement is marginal in this case. Again the optimal schedule uses dasatinib to reduce
the wild-type progenitor cell population, but switches to nilotinib much earlier to reduce
the wild-type differentiated cell and F317L cell popoluations.
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Figure 4. Plot of cell number versus time for three monotherapies
and optimal combination therapy for preexisting F317L, with no
toxicity constraints.
Incorporating toxicity constraints. We next study how drug toxicity affects the optimal
therapy, in particular with the drug toxicity constraint introduced in the Toxicity Mod-
eling subsection. Recall that the toxicity constraint prevents ANC from dipping below a
threshold value Lanc. The ANC decreases at a constant rate each month under each drug,
and increases at a constant rate without drug. The ANC never exceeds the normal level
of Uanc. We first assume that nilotinib has a higher toxicity than dasatinib, and dasatinib
has a higher toxicity than imatinib. In particular, the monthly decrease rates of ANC for
nilotinib, dasatinib, and imatinib are 350/mm3, 300/mm3, and 250/mm3, respectively, and
ANC increases by 2, 000/mm3 with one month drug holiday.
We incorporated the toxicity constraints into the preexisting M351T mutant scenario
described previously, i.e. initial cell populations are given in Table 2. The three monother-
apies and resulting optimal combination therapy are shown in Table 5 below. Note that
the proposed combination therapy is very close to the one described without toxicity con-
straints (i.e., Table 3), except now drug holidays are inserted to maintain the ANC level
above Lanc.
Table 5. Treatment schedules with drug toxicities.
Nilotinib 1 1 1 1 1 0 1 1 1 1 1 1 0 1 1 1 1 1 1 0 1 1 1 1 1 0 1 1 1 1 1 1 0 1 1 1
Dasatinib 2 2 2 2 2 2 0 2 2 2 2 2 2 2 0 2 2 2 2 2 2 0 2 2 2 2 2 2 2 0 2 2 2 2 2 2
Imatinib 3 3 3 3 3 3 3 0 3 3 3 3 3 3 3 3 0 3 3 3 3 3 3 3 3 0 3 3 3 3 3 3 3 3 0 3
Combination 2 0 2 2 2 2 2 2 0 2 2 2 2 2 2 0 2 2 2 2 2 2 0 2 2 2 2 2 2 0 2 2 1 1 1 1
The cell dynamics of three monotherapies and the proposed combination therapy are
given in Fig 5. It can be seen that after drug holidays, the total leukemic cell population
almost returns to the level at the beginning of treatment. This indicates that a one month
drug holiday may be too long for the patient.
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Figure 5. Plot of cell number versus time for three monother-
apies and optimal combination therapy for preexisting M351T,
incorporating toxicity constraints.
Since it is not clear whether nilotinib or dasatinib result in higher toxicity effects, we also
switched the monthly ANC depletion rates to nilotinib - 300, dasatinib - 350, and imatinib
- 250, so that dasatinib has the highest toxicity. Other conditions are kept the same. The
recommended combination therapy is shown in Table 6 below. Note that now imatinib is
used more frequently, due to the increase in toxicity of dasatinib. We also compare the
performance of the four different schedules in Fig 6.
Table 6. The optimal treatment schedules with different drug toxicities.
Nilotinib>Dasatinib 2 0 2 2 2 2 2 2 0 2 2 2 2 2 2 0 2 2 2 2 2 2 0 2 2 2 2 2 2 0 2 2 1 1 1 1
Dasatinib>Nilotinib 2 0 2 2 2 2 2 0 3 2 2 2 2 2 0 3 2 2 2 2 2 0 3 2 2 2 2 2 0 3 3 1 1 1 1 1
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Figure 6. Plot of cell number versus time for three monotherapies
and optimal combination therapy for preexisting M351T, incorpo-
rating toxicity constraints. Here it is assumed that the ANC reduction
rate during dasatinib treatment is higher than during nilotinib treatment.
Multiple mutants preexisting before the initiation of therapy. Lastly we investigate how
much gain can be expected from combination therapy if more than one mutant type pre-
exists before initiation of therapy. We again consider an optimization model over a 36
month horizon. We assume mutants M351T and F317L preexist therapy at a low level
(each consists of 5% of the total leukemic cell population); the initial conditions are given
in Table 7. The recommended combination therapy is the same as the recommended ther-
Table 7. The initial cell abundance.
Normal cell Wild-type M351T F317L
SC 7.34× 104 2.66× 105 1.48× 104 1.48× 104
PC 1.61× 107 3.66× 107 2.04× 106 2.04× 106
DC 3.24× 109 9.72× 109 5.40× 108 5.40× 108
TC 3.24× 1011 9.72× 1011 5.40× 1010 5.40× 1010
apy when only one mutant F317L is present. The result is reasonable since the F317L has
higher resistance to our therapies, and thus has a more significant impact on the structure
of the optimal treatment schedule.
We now assume that the two mutants present are E255K and F317L. According to the
in vitro IC50 value reported in [23], E255K is resistant to each drug. The recommended
combination therapy is shown in Table 8 below. The combination therapy is different from
the combination therapies proposed in the baseline model and the model with M351T and
F317L, and is close to the monotherapy with dasatinib. We also compare the performance
Table 8. The optimal treatment schedules with two mutants.
M351T 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1 1 1 1
F317L 2 2 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M351T & F317L 2 2 2 2 2 2 2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
F317L & E255K 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 1 1
of the four different schedules in Fig 7. The leukemic cell population is driven down in
the first several months, but increases thereafter due to the increase of E255K population.
Since E255K is resistant to each drug, even with the best therapy the leukemic cells still
consist of over 73.5% of the total cell population after 36 months. These results demonstrate
that the optimal combination schedule is strongly dependent upon the specific type and
combination of preexisting BCR-ABL mutants present at the start of therapy.
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Figure 7. The cell dynamics with F317L and E255K preexisting therapy.
Discussion
In this work we have considered the problem of finding optimal treatment schedules for
the administration of a variety of TKIs for treating chronic phase CML. We modeled the
evolution of wild-type and mutant leukemic cell populations with a system of ordinary
differential equations, and incorporated a dynamics model of patient ANC level to account
for toxicity constraints. We then formulated an optimization problem to find the sequence
of TKIs that lead to a minimal cancerous cell population at the end of a fixed time horizon
of 36 months. The 36 month therapeutic horizon is clinically meaningful since it appears
that the risk of therapeutic failure and disease progression to blast crisis is highest within
the first two years from diagnosis [1].
At first glance the optimization problem studied in this work (OTP) is quite challenging.
It is a mixed-integer nonlinear optimization problem, where the nonlinear constraints are
specified by the solution to a nonlinear system of differential equations. However, one
factor mitigating the complexity of the problem is the assumption that the TKIs do not
effect the stem cell compartment. This has the effect of making the evolution of the stem
cell compartment independent of the TKI schedule chosen. In addition, the remaining
layers in the cellular hierarchy are modeled by linear differential equations. We can thus
numerically solve the differential equation governing the stem cell layer, and treat this
function as an inhomogeneous forcing term in the linear differential equation governing the
progenitor cells. This allows us to approximate the nonlinear constraints specified by the
differential equations by linear constraints with high accuracy. Then the OTP problem
can be approximated by a mixed-integer linear optimization problem, which we are able
to solve with state-of-the-art optimization software CPLEX [27] within one hour.
Importance of minimizing progenitor cell population. We first aimed to minimize leukemic
cell burden at 36 months after initiation of therapy, starting with an initial leukemic popu-
lation of wild-type CML cells and either M351T (sensitive to all three therapies) or F317L
(resistant to dasatinib) mutant leukemic cells. For both starting mutant populations, we
observed that the optimal schedule involves initiating therapy with dasatinib and later
switching to nilotinib, although the timing of the switch differed. To further understand
this result, we noted that within this parameter regime, dasatinib is the most effective
of the three TKIs at controlling leukemic progenitor cells, while nilotinib is the most ef-
fective at controlling the differentiated cells, which comprise most of the total leukemic
burden. Thus, we note that controlling the leukemic progenitor cell population is impor-
tant in long-term treatment outcome. This is further supported by the observation that
blast crisis emerges due the acquisition of additional mutations in CML progenitor cells
(not stem cells) [3]. Our approach suggests that using combination TKI therapies may be
a viable method of controlling this population. Our modeling suggests that it is best to
reduce the progenitor cells early and then reduce the differentiated cells towards the end
of the treatment planning horizon. An early reduction in progenitor cells pays off in later
stages of the treatment planning horizon, since a small progenitor cell population results in
a lower growth rate for differentiated cells which leads to a greater response to subsequent
TKI therapy.
Effects of toxicity constraints. We also imposed a toxicity constraint on therapy opti-
mization procedure by mandating that patient ANC levels stay above a given threshold
that reduces the risk of infections. We observed that incorporating this toxicity constraint
does impact the structure of the optimal schedules significantly, resulting in mandated
treatment breaks as well as switching some months to imatinib therapy, which has a lower
toxicity effect. We also noted that the choice of treatment breaks occurring also in one-
month intervals may result in dangerous rebound of leukemic burden to levels close to
pre-treatment, suggesting that shorter breaks to combat toxicity may be recommended.
Although the model we have used for describing the dynamics of the ANC levels is simple,
our findings demonstrate that incorporating a mechanistically modeled toxicity constraint
into optimization of therapy scheduling is both feasible and important in determining op-
timal scheduling.
Multiple preexisting mutant types. While some previous studies have suggested that the
majority of CML patients are diagnosed with 0 or 1 preexisting BCR-ABL mutations, some
patients do harbor multiple mutants at the start of therapy [2, 6]. Thus we also investigated
the impact of having 2 mutant types present (M351T and F317, or E255K and F317L) at the
start of therapy, on optimal schedules. We observed the number and specific combination
of preexisting mutants present can significantly impact the optimization results. This
points to the importance of determining which BCR-ABL mutations preexist in patients
at diagnosis, before treatment planning is done.
Throughout this work we have observed that the structure of the optimal therapy de-
pends heavily on model parameters, e.g., cellular growth rates and ANC decay rates. It
is likely that each individual patients will have unique model parameters, and therefore a
unique best schedule. An exciting application of this work would be the development of
personalized optimal therapeutic schedules. Determination of (i) the mutant types (if any)
present in a patient’s leukemic cell population, (ii) growth kinetics of their leukemic cell
populations, and (iii) patient ANC level responses under various TKIs, would enable our
optimization framework to build treatment schedules in a patient-specific setting.
A. Parameters
In this section we describe the model parametrization for the examples shown above.
A major source of our parameters is the work [20] which statistically fit a hierarchical
differential equation model (similar to (2)) to time series data of CML patents undergoing
TKI therapy.
A.1. Stem cell kinetics.
• Density dependence parameters φi of type i stem cell, for each i. We have φi =
1/(1 + pi
∑n
i=1 x1,i(t)), with p1 = (b
0
1,1/d
0
1,1 − 1)/K1, p2 = (b01,2/d01,2 − 1)/K2, and
pi = p2 for i ≥ 3. The values of K1 and K2 are given in Section A.5.
• The birth rates bj1,i. The estimates bj1,1 = 0.008 and bj1,i = 0.01 for any cell type
i ≥ 2 and drug j. The value 0.01 is used in [20] for the birth rate of leukemic stem
cells without drug. We further assume that this value remains the same under any
therapy, which is different from [20].
• The death rates dj1,i. The estimate dj1,i = 0.0005 for any i and j, from [20].
A.2. Progenitor cell kinetics.
• The death rates dj2,i. The estimates d12,i = 0.0028 and d22,i = 0.0053 for any i,
from [20]. The death rate of leukemic progenitor cells under high-dose imatinib (800
mg/day) is 0.0035 in [20]. We consider imatinib with regular dose (400 mg/day)
in this paper, so we set d32,i = 0.0035/2 = 0.00175 for any i. Note the death rates
are the same across all cell types with the same therapy, but vary with different
therapies. In addition, we set the death rate of normal progenitor cells d02,i =
min{d12,i, d22,i, d32,i} = 0.00175 for any i.
• The differentiation rates bj2,i.
– For normal cells, bj2,1 = 0.35 for any j.
– For wild type, b02,2 = 2b
j
2,1 = 0.70, b
1
2,2 = b
0
2,2/400 = 0.00175, b
2
2,2 = b
0
2,2/200 =
0.0035, and b32,2 = b
0
2,2/400 = 0.00175. All estimates are from [20].
– For mutants, the differentiation rates are listed in Table 9. Since there are
little in vivo data available in the literature related to leukemic mutant birth
rate, our estimation is based on in vitro data for these mutants, in particular
the IC50 values. We use a piecewise linear interpolation to estimate the differ-
entiation rates, based on the relative IC50 values of mutants under nilotinib,
dasatinib, and imatinib reported in [23]. For sensitive or moderately resistant
mutants (the relative IC50 value is less than or equal to 4), the differentiation
rate of mutant i is estimated using the linear interpolation
bj2,i = relative IC50 value of mutant i under drug j × bj2,2.
For resistant mutants (the relative IC50 value is between 4.01 and 10), the
differentiation rate is estimated with the following linear interpolation:
bj2,i = 0.9b
4
2,2 +
0.1b42.2
10− 4.01(relative IC50 value of mutant i under drug j − 4.01).
Thus if the relative IC50 value for a resistant mutant is 4.01, then its differen-
tiation rate is 90% of the differentiation rate of the WT cell without any drug
(0.7 per day); if the relative IC50 value for a resistant mutant is 10, then its
differentiation rate is equal to the birth rate of the WT progenitor cell without
drug. For highly resistant mutants (the relative IC50 is larger than 10), we
set its differentiation rate to the differentiation rate of the WT progenitor cells
without drug.
A.3. Differentiated cell kinetics.
• The death rate dj3,i. The estimates d13,i = 0.0442 and d23,i = 0.0394 for any i,
from [20]. The death rate of leukemic differentiation cells under high-dose imatinib
Table 9. The differentiation rate of mutant progenitor cells under three drugs
E255K E255V F317L M351T Y253F V299L
Nilotinib (b12,i) 0.6614 0.7 0.00389 0.00077 0.00565 0.00235
Dasatinib (b22,i) 0.6488 0.0120 0.6354 0.00308 0.00553 0.6843
Imatinib (b32,i) 0.6536 0.7 0.00455 0.00308 0.00627 0.00270
(800 mg/day) is 0.055 in [20]. We consider imatinib with regular dose (400 mg/day)
in this paper, so we set d33,i = 0.055/2 = 0.0275 for any i. In addition, d
0
3,i =
min{d13,i, d23,i, d33,i} = 0.0275 for any i.
• The differentiation rates bj3,i.
– For normal cells, bj3,1 = 5.5 for any j.
– For wild type, b03,2 = 1.5b
0
3,1 = 8.25, b
1
3,2 = b
0
3,2/600 = 0.01375, b
2
3,2 =
b03,2/300 = 0.0275, and b
3
3,2 = b
0
3,2/600 = 0.01375. All estimates are from [20].
– For the mutant, if it is sensitive or moderately resistant to drug j (the relative
IC50 value is less than or equal to 4), then bj3,3 = b
j
2,3× bj3,2/bj2,2, for j = 1, 2, 3;
otherwise bj3,3 = b
j
2,3 × b43,2/b42,2, for j = 1, 2, 3.
A.4. Terminally differentiated cell kinetics. Using the estimates from [20], we set the
differentiation rates bj4,i = 100 and death rates d
j
4,i = 1 for any i and j.
A.5. Initial cell populations at diagnosis. The normal marrow output in an adult is
approximately 3.5 × 1011 cells per day [26]. To achieve this equilibrium condition, we set
K1 = 8.75 × 104 in differential equations (2) with parameters described in Sections A.1
to A.4 and in the absence of leukemic cells. To obtain an estimate of K2, we assume that
diagnosis of CML occurs once the leukemic cell burden reaches a threshold of 1012 cells [25],
and that the differential equations (2) have parameters described in Sections A.1 to A.4
and start with K1 = 8.75 × 104 normal stem cells, one wild-type leukemic stem cell, and
no other cells. We set K2 = 3 × 106 so that the patient is diagnosed with CML around
78 months (6.5 years) after the first leukemic stem cell arises. At diagnosis, the normal
stem cell, progenitor cell, differentiated cell, and terminally differentiated cell populations
are 7.34 × 104, 1.61 × 107, 3.24 × 109, and 3.24 × 1011, respectively; the leukemic stem
cell, progenitor cell, differentiated cell, and terminally differentiated cell populations are
2.95 × 105, 4.07 × 107, 1.08 × 1010, and 1.08 × 1012 respectively. These are used as the
initial cell populations for a patient diagnosed with CML.
A.6. ANC kinetics.
• We require the patient’s ANC cannot fall below Lanc = 1000/mm3, the normal
level of ANC is Uanc = 3000/mm
3, and the patient’s initial ANC is 3000/mm3.
• It is observed that nilotinib has higher toxicity than imatinib [28]. We set the
estimated monthly decrease rates of ANC to be danc,1 = 350/mm
3 under nilotinib,
danc,2 = 300/mm
3 under dasatinib, and danc,3 = 250/mm
3 under imatinib. The
ANC of a patient increases by banc = 2000/mm
3 during a drug holiday, before it
reaches the normal level 3000/mm3. We also investigate how optimal schedule is
affected if dasatinib has a higher toxicity than nilotinib, with danc,1 = 300/mm
3
and danc,2 = 350/mm
3.
B. Method to solve the optimization model
We describe the method to solve the optimization model (3) introduced in Section . Our
strategy is to build a mixed-integer linear optimization model [18] that approximates the
optimization model (3), and then solve the approximation model to optimality numerically
by off-the-shelf optimization software CPLEX [27]. The mixed-integer linear optimiza-
tion model is built through two steps: (1) we first approximate the ODE constraints (3b)
by bilinear constraints; (2) we then transform the bilinear constraints and nonlinear con-
straints (3d) into equivalent linear constraints, by adding auxiliary decision variables.
We first describe how to approximate the ODE constraints (3b) by bilinear constraints.
Suppose patients take drug j in month m. Since the cell dynamics are modeled by the
following set of ODEs
x˙(t) = f j(x(t)), t ∈ [m∆t, (m+ 1)∆t],(4a)
x(m∆t) = xm,(4b)
the cell abundances in month m + 1, xm+1, are completely determined by the initial cell
abundance xm and function f j . Without loss of generality, we assume this relationship is
described by
(5) xm+1l,i = g
j
l,i(x
m)
with some unknown nonlinear function gjl,i : R
Ln → R, for each month m, layer l, and cell
type i. Recall that L is total number of cell layers (L = 4), and n is the total number of
cell types. Then the ODE constraints (3b) are equivalent to the constraints below
(6) xm+1l,i =
∑
j∈J
zm,jgjl,i(x
m), for each m, l, i.
We will approximate the nonlinear function gjl,i with an affine function gˆ
m,j
l,i : R
Ln → R,
for each m, j, l, and i. In particular, the function
(7) gˆm,jl,i (x) = a
j,l,ix+ hm,jl,i ,
where aj,l,i is an (Ln)-dimensional vector and does not depend on m. Details of how gˆm,jl,i is
constructed are provided in Section C of the Appendix. Let aj,l,i = [aj,l,i1,1 , . . . , a
j,l,i
k,s , . . . , a
j,l,i
L,n].
Then constraint (6) can be approximated by the bilinear constraint
(8) xm+1l,i =
∑
j∈J
zm,j gˆm,jl,i (x
m) =
∑
j∈J
zm,j(
∑
k∈L,s∈I
aj,l,ik,s x
m
k,s + h
m,j
l,i ),
for each type i cell at layer l in month m.
We now describe how to transform bilinear constraints (8) and piecewise linear con-
straints (3d) into linear constraints. These are standard techniques in mixed-integer lin-
ear optimization [18]. We introduce auxiliary continuous variables vm,jk,s , and set v
m,j
k,s =
zm,jxmk,s. Then bilinear constraints (8) are transformed into the equivalent linear constraints
below.
xm+1l,i =
∑
j∈J
(
∑
k∈L,s∈I
aj,l,ik,s v
m,j
k,s + h
m,j
l,i z
m,j)
0 ≤vm,jk,s ≤ Uk,szm,j ,
0 ≤xmk,s − vm,jk,s ≤ Uk,s(1− zm,j),
(9)
where Uk,s is an upper bounds of cell abundance x
m
k,s for each m. The value of Uk,s can be
obtained by taking the maximum value of layer k type s cell abundances over the whole
planning horizon under all three monotherapies and no treatment. The piecewise linear
constraints (3d) can be transformed into equivalent linear constraints below, by introducing
auxiliary continuous variable um and binary variable qm for each m.
um+1 = ym + banc −
∑
j∈J\{0}
danc,jz
m,j ,(10a)
ym+1 ≥ um+1 − bancqm+1,(10b)
ym+1 ≥ Uanc − (Uanc − Lanc)(1− qm+1),(10c)
ym+1 ≤ um+1,(10d)
ym+1 ≤ Uanc,(10e)
qm+1 ∈ {0, 1}.(10f)
Overall, the optimization model (3) is approximated by the following mixed-integer linear
optimization model.
min
∑
l≥1
∑
i≥2
xMl,i(11a)
s.t. xm+1l,i =
∑
j∈J
∑
k∈L,s∈I
aj,l,ik,s v
m,j
k,s +
∑
j∈J
hm,jl,i z
m,j , i ∈ I, l ∈ L,m ∈M \ {M}(11b)
0 ≤ vm,jk,s ≤ Uk,szm,j , i ∈ I, l ∈ L,m ∈M \ {M}(11c)
0 ≤ xmk,s − vm,jk,s ≤ Uk,s(1− zm,j), i ∈ I, l ∈ L,m ∈M \ {M}(11d)
um+1 = ym + banc −
∑
j∈J\{0}
danc,jz
m,j , m ∈M \ {M}(11e)
ym+1 ≥ um+1 − bancqm+1, m ∈M \ {M}(11f)
ym+1 ≥ Uanc − (Uanc − Lanc)(1− qm+1), m ∈M \ {M}(11g)
ym+1 ≤ um+1, m ∈M \ {M}(11h)
ym+1 ≤ Uanc, m ∈M \ {M}(11i)
ym ≥ Lanc, m ∈M(11j) ∑
j∈J
zm,j = 1, m ∈M \ {M}(11k)
zm,j , qm+1 ∈ {0, 1}, m ∈M \ {M}, j ∈ J(11l)
x(0) = x0, y0 is given.(11m)
C. Linear approximation to the solutions of the ODEs
In this section, we describe how to construct the affine function gˆm,jl,i in (7) in Section B
of the Appendix. If we assume that the drugs do not affect stem cells, we can compute the
abundance of stem cells over the planning horizon numerically in advance, regardless of
the treatment schedules. Thus we assume x1,1(t), . . . , x1,n(t) are given as data, for any t.
We can first eliminate all the variables xm1,i and constraints containing x
m
1,i, for each m and
i, in the optimization problem (11). The dynamics of wild-type leukemic cells and each
mutant type have no impact on each other. We can decouple the ODEs into a series of
linear ODEs as follows, each describing the dynamics for type i cell from layer 2 to layer 4.
(12)
 x˙2,i(t)x˙3,i(t)
x˙4,i(t)
 =
 −d
j
2,i 0 0
bj3,i −dj3,i 0
0 bj4,i −dj4,i

 x2,i(t)x3,i(t)
x4,i(t)
+
 bj2,ix1,i(t)0
0

Write the above equations in the matrix form, we have
(13) v˙i(t) = W
j
i vi(t) + w
j
i (t), for t ∈ [m∆t, (m+ 1)∆t],
where vi(t) = [x2,i(t), x3,i(t), x4,i(t)]
>, wji (t) = [b
j
2,ix1,i(t), 0, 0]
>, and W ji is the lower tri-
angular matrix in (12).
We divide (m∆t, (m+1)∆t) into ∆t = 30 one-day sub-intervals. Consider a sub-interval
(t0, t0 +1). By assuming w
j
i (t) = w
j
i (t0) for any t ∈ (t0, t0 +1), we solve (13) approximately
and obtain
(14) vi(t0 + 1) ≈ eW
j
i vi(t0) + (e
W ji − I)(W ji )−1wji (t0).
By combining equations (14) for t0 = m∆t,m∆t+ 1, . . . , (m+ 1)∆t− 1, we have
(15) vi((m+ 1)∆t) = e
W ji ∆tvi(m∆t) +
∆t−1∑
d=0
eW
j
i (∆t−1−d)(eW
j
i − I)(W ji )−1wji (m∆t+ d).
Recall that vi(m∆t) = [x
m
2,i, x
m
3,i, x
m
4,i]
> for each m. Thus (15) can be rewritten as
(16)
 xm+12,ixm+13,i
xm+14,i
 = Aj,i
 xm2,ixm3,i
xm4,i
+ hm,ji ,
where Aj,i = (eW
j
i )∆t and hm,ji =
∑∆t−1
d=0 (e
W ji )∆t−1−d(eW
j
i − I)(W ji )−1wji (m∆t+ d). Each
equation in (16) is used as the affine function gˆm,jl,i in (7), for each m, j, i, and l = 2, 3, 4.
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